Zimbuck – Your Market. Your Community.
Exagen (NASDAQ: XGN) fell 26% to $5.26 on Tuesday after its Q3 EPS missed estimates. The precision-medicine company reported a loss of $0.25 per share, even as revenue rose 7% to a record $18.4M. Net loss narrowed to $6.3M, cash stood at $28.1M, and full-year 2026 revenue guidance was reiterated at $72M-$75M.
#Exagen #XGN #Earnings #Stocks #Biotech #StockMarket
Like
Love
9
107 Views